DRTSW

Investor Moves

Name	Value	Action	Change	Price	Current Price
Ken GriffinCitadel Advisors $-7.3K ExitQ3 2025 $7.3k -- --
Ken GriffinCitadel Advisors $-2.4K TrimQ2 2025 $2.4k -- --

Insider Trades

Name	Value	Action	Price	Current Price
Levy RaphiChief Financial Officer $191k17.5k shares SellJun 3, 2026 $10.90 --
Levy RaphiChief Financial Officer $161k15k shares SellJun 3, 2026 $10.76 --

Trade DRTSW

About Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd. is a clinical-stage biopharmaceutical company dedicated to the research, development, and eventual commercialization of innovative cancer treatments. Its primary focus is on Alpha DaRT (diffusing alpha-emitters radiation therapy), a novel approach designed to effectively treat solid tumors. The company's initial commercialization efforts are concentrated in Israel and the United States. Currently, Alpha DaRT is undergoing clinical trials for various malignancies, including skin, oral, pancreatic, and breast cancers. Beyond this, preclinical studies are investigating its potential efficacy against hepatic cell carcinoma, lung, and prostate cancers. Established in 2015, Alpha Tau Medical maintains its headquarters in Jerusalem, Israel.

CEO: Uzi Sofer
IPO Date: Mar 8, 2022

Market Data

Open: $1.84
High: $1.96
Low: $1.81
Volume: 16.9K
Avg Volume: 31.2K
52W High: $2.14
52W Low: $0.3251

Valuation

Market Cap: $883.4M
Enterprise Value: $889.3M
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$32.8M
Revenue: $0
Net Income: -$42.6M
Cash: $16M
Debt: $13.7M

Events

EarningsAug 18

EPS est. -0.14088